• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GEMCITABINE Drug Record

  • Summary
  • Interactions
  • Claims
  • GEMCITABINE chembl:CHEMBL888 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    GEMZAR
    LY188011
    GEMCITABINE
    NSC-613327
    LY-188011
    2',2'-DIFLUORODEOXYCYTIDINE
    4-AMINO-1-((2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL)-TETRAHYDROFURAN-2-YL)PYRIMIDIN-2(1H)-ONE
    GEMCITABIN
    GEMCITABINA
    GEMZAR®
    2'-DEOXY-2',2'-DIFLUOROCYTIDINE
    GEMCITABINUM
    GEMCITABINE HYDROCHLORIDE
    chembl:CHEMBL888
    pubchem.compound:60750
    chemidplus:95058-81-4
    rxcui:12574
    drugbank:00441

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (6 More Sources)

    Publications:

    Kim et al., 2016, Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study., Int. J. Radiat. Oncol. Biol. Phys.
    Knights J et al., 2014, Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity., Pharmacogenet Genomics
    Woo HI et al., 2012, Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine., Pharmacogenomics
    Infante et al., 2017, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors., Clin. Cancer Res.
    Osborne et al., 2016, Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)., J. Med. Chem.
    Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.
    Rajeshkumar et al., 2011, MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts., Clin. Cancer Res.
    Kreahling et al., 2013, Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas., PLoS ONE
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
    Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
    Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
    Liu et al., 2015, WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients., Sci Rep
    Alvarellos ML et al., 2014, PharmGKB summary: gemcitabine pathway., Pharmacogenet Genomics
    Liu ZQ et al., 2014, Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis., PLoS One
    Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer
    Maréchal R et al., 2012, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma., Gastroenterology
    Tanaka M et al., 2010, Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer., Cancer
    Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.
    Maring et al., 2005, Genetic factors influencing pyrimidine-antagonist chemotherapy., Pharmacogenomics J.
    Vernejoul et al., 2006, Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth., Mol. Ther.
    Lam et al., 2007, The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine., Mol. Pharmacol.
    Hsu et al., 2005, Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium., Mol. Pharmacol.
    Ryu JS et al., 2011, Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum., J Thorac Oncol
    Mitra AK et al., 2012, Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors., Pharmacogenomics
    Ellsworth KA et al., 2013, Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma., PLoS One
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Kadera et al., 2015, Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition., Clin. Cancer Res.
    Khatri A et al., 2014, SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours., Br J Cancer
    Angevin et al., 2017, Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study., Eur. J. Cancer
    Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
    Ziemke M et al., 2017, Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer., Lung Cancer
    Innocenti F et al., 2019, An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)., Pharmacogenet Genomics
    Soo RA et al., 2009, Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients., Lung Cancer
    Yang Z et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy., EBioMedicine
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
    Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer
    Van Laethem et al., 2017, Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer., Target Oncol
    O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.
    Mahalingam et al., 2015, The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer., BMC Cancer
    Infante et al., 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas., Eur. J. Cancer
    Kim et al., 2011, Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy., Mol. Cancer Ther.
    Labroli MA et al., 2014, The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors., Bioorg Med Chem
    Kwon et al., 2006, Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines., Pharmacogenet. Genomics
    Smid et al., 2006, Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits., Nucleosides Nucleotides Nucleic Acids
    Bepler et al., 2006, RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer., J. Clin. Oncol.
    Cerqueira et al., 2007, Understanding ribonucleotide reductase inactivation by gemcitabine., Chemistry
    Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
    Nakahira et al., 2007, Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer., Int. J. Cancer
    Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.
    Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE
    Akita et al., 2009, Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma., Oncogene
    Nie et al., 2013, The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer., Cancer Biomark
    Rosell R et al., 2004, Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Rosell R et al., 2004, Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery., Clin Cancer Res
    Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
    Miyazawa et al., 2010, Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer., Cancer Sci.
    Matthews et al., 2007, Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo., Cell Cycle
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Lee et al., 2006, Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer., Jpn. J. Clin. Oncol.
    van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
    Kroep et al., 2002, Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity., Mol. Cancer Ther.
    Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics
    Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
    Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
    Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.
    Xu et al., 2016, CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine., Oncotarget
    Kiyotani K et al., 2012, A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy., Pharmacogenet Genomics
    Baker JA et al., 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase., Drug Metab Dispos
    Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
    Verma et al., 2006, Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis., Cancer Res.
    Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget
    McCaffery I et al., 2013, Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor., Clin Cancer Res
  • GEMCITABINE   CMPK1

    Interaction Score: 2.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16041392 17000136 17565005 15550676 21642870 22838949 22838950 24361227


    Sources:
    PharmGKB

  • GEMCITABINE   DAPK1

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22293537


    Sources:
    PharmGKB

  • GEMCITABINE   TENT4A

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838950


    Sources:
    PharmGKB

  • GEMCITABINE   CIP2A

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26894380


    Sources:
    CIViC

  • GEMCITABINE   CDC5L

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838950


    Sources:
    PharmGKB

  • GEMCITABINE   SH2D5

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838950


    Sources:
    PharmGKB

  • GEMCITABINE   FHL2

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • GEMCITABINE   DCTD

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838950


    Sources:
    PharmGKB

  • GEMCITABINE   ALG10

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24225399


    Sources:
    PharmGKB

  • GEMCITABINE   RRM1

    Interaction Score: 0.98

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name gemcitabine HCl,Gemzar
    Novel drug target Established target

    PMIDs:
    24588962 16708051 17065054 16966686 17636467 16807441 17131328 23038758 24647522 19543324 24595080 14977831 15217961


    Sources:
    DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial CIViC

  • GEMCITABINE   CDSN

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   ETS2

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   DOCK8

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   MUCL3

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   SLC29A3

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   PPP1R18

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   MSH5

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   NT5C

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786


    Sources:
    PharmGKB

  • GEMCITABINE   C6ORF15

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   XYLT2

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   ATAT1

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   SLC28A1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30889042 25162786 18538445


    Sources:
    PharmGKB

  • GEMCITABINE   NT5C3A

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838949


    Sources:
    PharmGKB

  • GEMCITABINE   GPX5

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • GEMCITABINE   NT5C1A

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26906009


    Sources:
    PharmGKB

  • GEMCITABINE   PRRC2A

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   SLC29A2

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786


    Sources:
    PharmGKB

  • GEMCITABINE   HCP5

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   NT5C2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24300978 22838949


    Sources:
    PharmGKB

  • GEMCITABINE   DCK

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786 23230131 22705007 20665488 12477049


    Sources:
    PharmGKB

  • GEMCITABINE   SLC29A1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786 24475233 24361227 22705007 20665488


    Sources:
    PharmGKB

  • GEMCITABINE   SLC28A3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786 24300978


    Sources:
    PharmGKB

  • GEMCITABINE   SLC28A2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20665488 18538445


    Sources:
    PharmGKB

  • GEMCITABINE   POLR1G

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   PSORS1C1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   PPP1R13L

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   SERPINA5

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   FANCC

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16243825


    Sources:
    CIViC

  • GEMCITABINE   CDA

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12477049


    Sources:
    NCI

  • GEMCITABINE   ACSS2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • GEMCITABINE   POLR2A

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   SMAD4

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type decreased response

    PMIDs:
    22753594 28577946


    Sources:
    JAX-CKB CIViC

  • GEMCITABINE   CBL

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Emerging
    Approval Status Preclinical - Cell line xenograft
    Response Type predicted – sensitive

    PMIDs:
    25348515


    Sources:
    JAX-CKB

  • GEMCITABINE   PPCDC

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   KLC3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   ERCC1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17229776 16980606


    Sources:
    CIViC PharmGKB

  • GEMCITABINE   ATRX

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gemcitabine + Radiotherapy
    Indication/Tumor Type malignant glioma
    Response Type predicted – sensitive

    PMIDs:
    26853339


    Sources:
    JAX-CKB

  • GEMCITABINE   XRCC1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19157633


    Sources:
    CIViC

  • GEMCITABINE   WEE1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26057002


    Sources:
    CIViC

  • GEMCITABINE   HLA-C

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   FKBP5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23936393


    Sources:
    PharmGKB

  • GEMCITABINE   RRM2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial TTD

  • GEMCITABINE   IGF2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23741071


    Sources:
    CIViC

  • GEMCITABINE   RRM2B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • GEMCITABINE   RAF1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • GEMCITABINE   ERCC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   CASP7

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22441531


    Sources:
    PharmGKB

  • GEMCITABINE   CDKN2A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PD0332991 + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type decreased response

    PMIDs:
    25156567


    Sources:
    JAX-CKB

  • GEMCITABINE   TGM2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17079475


    Sources:
    NCI

  • GEMCITABINE   SERPINC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   NRG1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23390248


    Sources:
    CIViC

  • GEMCITABINE   BRCA2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29338080


    Sources:
    CIViC

  • GEMCITABINE   CYP2C8

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type biliary tract cancer
    combination therapy Panitumumab + Gemcitabine + Oxaliplatin
    Approval Status Phase Ib/II

    PMIDs:
    26540314 27975152 26091808 26156229 27167172 26228206 24915778 21862683


    Sources:
    JAX-CKB CIViC

  • GEMCITABINE   HRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16818479


    Sources:
    NCI

  • GEMCITABINE   CHEK1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17245119


    Sources:
    NCI

  • GEMCITABINE   NRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • GEMCITABINE   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12684687 29338080


    Sources:
    NCI CIViC

  • GEMCITABINE   SRC

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bosutinib + Gemcitabine
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive

    PMIDs:
    27196758


    Sources:
    JAX-CKB

  • GEMCITABINE   ESR2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838950


    Sources:
    PharmGKB

  • GEMCITABINE   FGFR3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29941343


    Sources:
    CIViC

  • GEMCITABINE   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • GEMCITABINE   PTEN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gemcitabine + LY2780301
    Indication/Tumor Type breast adenocarcinoma
    Response Type sensitive

    PMIDs:
    28750271


    Sources:
    JAX-CKB

  • GEMCITABINE   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    15581051


    Sources:
    JAX-CKB NCI

  • GEMCITABINE   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22285168 21783417


    Sources:
    PharmGKB

  • GEMCITABINE   ABCG2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Gemcitabine
    Indication/Tumor Type sarcoma
    Response Type sensitive

    PMIDs:
    27815358 27167172 26228206 21389100 23520471


    Sources:
    JAX-CKB

  • GEMCITABINE   KDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy VEGFR2-169 + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    19930156


    Sources:
    JAX-CKB

  • GEMCITABINE   PIK3CA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    28750271


    Sources:
    JAX-CKB

  • GEMCITABINE   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • GEMCITABINE   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gemcitabine + Radiotherapy
    Indication/Tumor Type malignant glioma
    Response Type predicted – sensitive

    PMIDs:
    26853339


    Sources:
    JAX-CKB

  • TdgClinicalTrial: GEMCITABINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: GEMCITABINE

    • Version: 14-September-2017

    Alternate Names:
    C961 NCI drug code

    Drug Info:

    Publications:
    Matthews et al., 2007, Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo., Cell Cycle
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.

  • DTC: GEMCITABINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL888 ChEMBL Drug ID

    Drug Info:

    Publications:
    Labroli MA et al., 2014, The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors., Bioorg Med Chem

  • JAX-CKB: Gemcitabine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Kim et al., 2016, Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study., Int. J. Radiat. Oncol. Biol. Phys.
    Osborne et al., 2016, Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)., J. Med. Chem.
    Kreahling et al., 2013, Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas., PLoS ONE

  • PharmGKB: gemcitabine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Knights J et al., 2014, Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity., Pharmacogenet Genomics
    Woo HI et al., 2012, Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine., Pharmacogenomics
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J

  • CIViC: GEMCITABINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    McCaffery I et al., 2013, Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor., Clin Cancer Res
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer

  • TTD: Gemcitabine

    • Version: 2020.06.01

    Alternate Names:
    D03UVS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL888

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: GEMCITABINE

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: GEMCITABINE

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21